Navigation Links
New class of cancer drugs could work in colon cancers with genetic mutation, U-M study finds
Date:4/25/2011

ANN ARBOR, Mich. A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

Working in cell lines from colorectal cancer patients, researchers found that a new class of drugs called PARP inhibitors worked against tumors with mutations in the MRE11 gene.

About 15 percent of all colorectal cancers have what's called microsatellite instability, a type of error in the DNA. About 82 percent of those tumors have the MRE11 gene mutation.

"This is a potential broader application for PARP inhibitors, beyond breast and ovarian cancer. This is a class of drug that's already shown safety in early clinical trials and now might benefit some colorectal cancer patients as well," says lead study author Eduardo Vilar-Sanchez, M.D., Ph.D., a hematology/oncology fellow at the U-M Medical School.

The study, which was published in Cancer Research, also found that PARP inhibitors are even more effective when both copies of MRE11 were mutated. Each person carries two copies of each gene, which means mutations can occur in either one or both copies. The researchers suggest that PARP inhibitors could be targeted specifically to colorectal cancer patients who have two copies of the mutated gene.

Researchers are planning a phase I clinical trial to look at using PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11. Future trials are being considered using PARP inhibitors to prevent colorectal cancer and other cancers in people with Lynch syndrome whose tumors have this mutation.

Microsatellite instability is also seen in prostate cancer and endometrial cancer, suggesting potential for PARP inhibitors to play a role in additional types of cancer as well, Vilar-Sanchez says, adding that more research is needed in these areas.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related medicine news :

1. Research Warns of Overuse of Powerful Class of Antibiotics
2. Social class makes no difference to water contamination risk
3. Classroom Environment May Affect Kids Mental Health
4. Study: Negative classroom environment adversely affects childrens mental health
5. Scripps Research and MIT scientists discover class of potent anti-cancer compounds
6. College Kids Often Feel Guilty About Texting in Class: Survey
7. Lung societies unveil new international classification of lung adenocarcinoma
8. New classification of sphincter of Oddi dysfunction
9. Social class and changes in mortality from liver cirrhosis over the 20th Century
10. Emerging drug class may enhance red blood cell production in anemic patients
11. How We Die, award-winning classic, updated for 2010
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New class of cancer drugs could work in colon cancers with genetic mutation, U-M study finds 
(Date:4/24/2017)... ... April 24, 2017 , ... ... seeking public support to bring their novel lifesaving device for the everyday use ... with medical-grade sensors, specially designed to read a child’s vital signs, and detect ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... are expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) ... greater use of this type of healthcare model in the diagnosis and treatment ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on May 20 ... an educational and exciting 2-day program. , An attendee at a recent PAINWeekEnd ... approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your SPIRITUAL COMPASS To Navigate ... Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the creation of published author, ... the Board of Directors for CONTACT USA, and former member of the American Association ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... the development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic ... manufacture its ANCD BRAIN device as the product advances towards regulatory and clinical ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 ... ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron ... announced the signing of a three-year exclusive sales ... deploy a dedicated sales team to introduce Imprimis, ... primarily focused in 13 states in the U.S. ...
Breaking Medicine Technology: